Oncimmune Holdings PLC | Key People and Executives
Geoffrey Neil Hamilton-Fairley
Chief Executive Officer & Director
Andrew Millet
CFO, Secretary & Executive Director
Annalisa Mary Jenkins
Non-Executive Director
Julian Clement Hirst
Non-Executive Director
Andrew Vaughan Unitt
Non-Executive Director
Richard S. Sharp
Non-Executive Director
Timothy Brian Bunting
Deputy Chairman
Carsten Schroeder
Non-Executive Director
Meinhard Folkert Schmidt
Non-Executive Chairman
Geoffrey Neil Hamilton-Fairley
Chief Executive Officer & Director
Andrew Millet
CFO, Secretary & Executive Director
Adam M. Hill
Chief Strategy & Medical Officer
James Jett
Chief Medical Officer
Maarten Brusse
Chief Commercial Officer-Asia Pacific Region
Shane Smith
Senior VP-Market Access & Reimbursement
Annalisa Mary Jenkins
Non-Executive Director
Julian Clement Hirst
Non-Executive Director
Andrew Vaughan Unitt
Non-Executive Director
Richard S. Sharp
Non-Executive Director
Timothy Brian Bunting
Deputy Chairman
Carsten Schroeder
Non-Executive Director
Delia Rivas
Vice President -Americas Sales
| Address |
Clinical Sciences Building
Nottinghamshire Nottingham NG5 1PB
United Kingdom
|
|
Employees
|
- |
| Website |
http://www.oncimmune.com |
| Updated |
07/08/2019 |
| Oncimmune Holdings Plc is an early cancer detection company that engages in the development and commercialization of its proprietary EarlyCDT platform technology. It has pioneer the development of tests based on the presence in the blood of autoantibody against specific tumor associated antigens that have the potential to detect cancer up to four years earlier than other methods of cancer detection, such as a chest X-ray, Spiral Computed Tomography or emerging technologies that do not benefit from the amplification of signal that occurs with the immune system, and can be applied to a very wide range of solid tumor types. The company was founded on October 9, 2015 and is headquartered in Nottinghamshire, the United Kingdom. |
